Tag: pharma regulatory challenges

In a dramatic shift in global trade policy, China has slashed import duties on Indian pharmaceutical products from 30% to 0% — a move many interpret as a strategic opening at a time when the United States plans to impose a 100% tariff on imported branded/patented drugs effective October 1, 2025. This twin development presents…